-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On December 8, the official website of the State Food and Drug Administration showed that the clinical application of Shenzhen Xinlitai Pharmaceutical's SAL0114 tablets was accepted by the State Food and Drug Administration.
The indications to be applied are severe depression, etc.
Depression is a common mental illness with high prevalence, recurrence and disabilit.
Studies have shown that the prevalence of depression in China has reached 2.1%; the lifetime prevalence of depression in Chinese adults is 6.8%, and the utilization of health services for patients with depression is low and they rarely receive adequate treatmen.
Most of the antidepressant drugs currently on the market take several weeks to take effect, and there are unmet clinical need.
With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expan.
Note: The original text has been deleted